Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind Phase III Clinical Study of QL1706 Versus QL1604 as Consolidation Treatment in Patients With Limited-stage Small Cell Lung Cancer Who Have Not Experienced Disease Progression After Concurrent or Sequential Chemoradiotherapy.

Trial Profile

A Randomized, Double-blind Phase III Clinical Study of QL1706 Versus QL1604 as Consolidation Treatment in Patients With Limited-stage Small Cell Lung Cancer Who Have Not Experienced Disease Progression After Concurrent or Sequential Chemoradiotherapy.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iparomlimab (Primary) ; Iparomlimab/tuvonralimab (Primary)
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Qilu Pharmaceutical

Most Recent Events

  • 02 Jun 2026 An interim analysis is planned as per trial design presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
  • 02 Jun 2026 Trial design presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
  • 02 Jun 2026 Status changed from not yet recruiting to recruiting as per trial design presented at the 62nd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top